Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$14.53 USD
-0.16 (-1.09%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $14.49 -0.04 (-0.28%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
PCRX 14.53 -0.16(-1.09%)
Will PCRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PCRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PCRX
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
PCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pacira (PCRX) Down 27.9% Since Last Earnings Report: Can It Rebound?
Pacira (PCRX) Plummets as US Court Deems Exparel Patent Invalid
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Other News for PCRX
Pacira BioSciences Inc (PCRX) Shares Up 5.26% on Sep 16
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Organon downgraded, Amneal upgraded as J.P. Morgan reviews specialty pharma
Pharmacorp Rx Inc. Expands with New Pharmacy Acquisition
PharmaCorp Completes Acquisition of a Pharmacy in Western Canada